Concepedia

Publication | Open Access

A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

DOIFull Paper Access

42

Citations

25

References

2014

Year

Kathryn A. Gold, J. Jack Lee, Nusrat Harun, Ximing Tang, Justina Price, Jitesh D. Kawedia, Hai T. Tran, Jeremy J. Erasmus, George R. Blumenschein, William Nassib William,
The Oncologist

Abstract

The combination of erlotinib and dasatinib is safe and feasible in NSCLC. The results of this study do not support use of this combination in molecularly unselected NSCLC.

References

YearCitations

Page 1